Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27

CAMBRIDGE, MA--(Marketwired - Sep 20, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the Boulder Peptide Symposium 2013. The conference is being held September 25-27, 2013, at the St Julien Hotel in Boulder, Colorado.

Terrence W. Norchi, MD, CEO of Arch Therapeutics, will provide an overview of the medical device Company's plan to commercialize novel products using their proprietary self-assembling peptide technology during a live presentation to a significant audience of conference attendees. If you are a member of the industry or a non-profit, academic, or government group, and would like to attend the Company's presentation, please click on the following link www.boulderpeptide.org to register for the Boulder Peptide Symposium 2013.

About Arch Therapeutics, Inc. (OTCQB: ARTH)
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures. Find out more at www.archtherapeutics.com.

About Boulder Peptide Society
The Boulder Peptide Society is a non-profit 501(3)c organization dedicated to supporting the advancement of peptide therapeutics. The Society organizes the Annual Boulder Peptide Symposium as a key vehicle for driving the science and technology in this important field.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

On Behalf of the Board,
Terrence W. Norchi, MD.
Arch Therapeutics, Inc.